Seminars in Colon & Rectal Surgery
Volume 18, Issue 4 , Pages 242-246 , December 2007

The Impact of Surgery on Angiogenesis

References 

  1. Allendorf JD, Bessler M, Horvath KD, et al. Increased tumor establishment and growth after open vs laparoscopic surgery in mice may be related to differences in postoperative T-cell function. Surg Endosc. 1999;13:233–235
  2. Kirman I, Cedik V, Poltaratskaia N, et al. Plasma from patients undergoing major open surgery stimulates in vitro tumor growth: lower insulin-like growth factor binding protein 3 levels may, in part, account for this change. Surgery. 2002;132:186–192
  3. Kirman I, Jain S, Cekic V, et al. Altered plasma matrix metalloproteinase-9/tissue metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer. Surg Endosc. 2006;20(3):482–486
  4. Parkin DM, Pisani P, Ferlay J. Global Cancer Statistics. CA Cancer J Clin. 1999;49:33–64
  5. Vermoken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage 2 and stage 3 human colon cancer: a randomized trial. Lancet. 1999;353:345–350
  6. Jagoditsch M, Lisborg PH, Jatzgo GR, et al. Long-term prognosis for colon cancer related to consistent radical surgery: multivariate analysis of clinical, surgical and pathologic variables. World J Surg. 2000;24:1264–1270
  7. Kirman I, Cekic V, Poltoratskaia N, et al. Open surgery induces a dramatic decrease in circulating intact IGFBP-3 in patients with colorectal cancer not seen with laparoscopic surgery. Surg Endosc. 2005;19:55–59
  8. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1990;82:4–6
  9. Folkman J. Addressing tumor blood vessels. Nat Biotechnol. 1997;15:510
  10. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9–22
  11. Sako A, Kitayama J, Yamaguchi H, et al. VEGF synthesis by omental mesothelial cells is augmented by fibroblast growth factor-2: Possible role of mesothelial cells on the development of peritoneal metastasis. J Surgical Research. 2003;115:113–120
  12. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439–442
  13. Karayiannakis AJ, Syrigos KN, Zbar A, et al. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery. 2002;131(5):548–555
  14. Sato K, Tsuchiya N, Sasaki R, et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res. 1999;90:874–879
  15. Werther K, Christensen IJ, Nielsen HJ, et al. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer. 2002;86:417–423
  16. Takeda A, Shimada H, Imaseki H, et al. Clinical significance of serum endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep. 2000;7:333–338
  17. Belizon A, Balik E, Kirman I, et al. Major abdominal surgery increases plasma levels of vascular endothelial growth factor; open more so than minimally invasive methods. Ann Surg. 2006;244(5):792–798
  18. Karayiannakis AJ, Syrigos N, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients. Ann Surg. 2002;236(1):37–42
  19. Curigliano G, Petit JY, Bertolini F, et al. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. Breast Cancer Res Treat. 2005;93(1):35–40
  20. DeVita F, Orditura M, Lieto E, et al. Elevated perioperative serum VEGF levels in patients with colon carcinoma. Cancer. 2004;100:270–278
  21. Kumar H, Heer K, Lee PW, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res. 1998;4:1279–1285
  22. Hyodo I, Doi T, Endo H, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer. 1998;34:2041–2045
  23. Kitamura M, Toi M, Arai K, et al. Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol Rep. 1998;5:1419–1424
  24. Werther K, Christensen IJ, Brunner N, et al. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma (The Danish RANX05 Colorectal Cancer Study Group). Eur J Surg Oncol. 2000;26(7):657–662
  25. Svensen CH. Vascular endothelial growth factor (VEGF) in plasma increases after hip surgery. J Clin Anesth. 2004;16(6):435–439
  26. Wu FPK, Westphal JR, Hoekman K, et al. The effects of surgery, with and without rhGMCSF, on the angiogenic profile of patients treated for colorectal carcinoma. Cytokine. 2004;25:68–72
  27. Ikeda M, Furukawa H, Imamura H, et al. Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor. Gastric Cancer. 2002;5:137–141
  28. Banks RE, Forbes MA, Kinsey SE, et al. Release of the cytokine vascular endothelial growth fctor (VEGF) from platelets: Significance for VEGF measurements and cancer biology. Br J Cancer. 1998;77:956–964
  29. Nielsen HJ, Werther K, Mynster T, et al. Soluble vascular endothelial growth factor (VEGF) in various blood transfusion components. Transfusion. 1999;39:1078–1083
  30. Salven P, Orpana A, Joensuu H, et al. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res. 1999;5:487–491
  31. Sako A, Kitayama J, Yamaguchi H, et al. VEGF synthesis by omental mesothelial cells is augmented by fibroblast growth factor-2: Possible role of mesothelial cells on the development of peritoneal metastasis. J Surgical Research. 2003;115:113–120
  32. Pham I, Uchida T, Planes C, et al. Hypoxia upregulates VEGF expression in alveolar epithelial cells in vitro and in vivo. Am J Physiol Lung Cell Mo Physiol. 2002;283:L1133–L1142
  33. Lolmede K, Durande de Saint Front V, Galitzky J, et al. Effects of hypoxia on the expression of proangiogenic factors in diffetentiated 3T3-F442A adipocytes. International J Obesity. 2003;27:1187–1195
  34. Karayiannakis AJ, Syrigos N, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients. Annals of Surgery. 2002;236(1):37–42
  35. Belizon A, Horst P, Balik E, et al: Persistent elevation of plasma VEGF levels during the first month following minimally invasive colorectal resection. Accepted for publication: Surgical Endoscopy, In Press.
  36. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91(3):173–180
  37. McCrudden KW, Hopkins B, Frischer J, et al. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg. 2003;38(3):308–314discussion 308-314.
  38. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2(4):306–314
  39. Giantonio BJ, Catalano PJ, Meropol NJ. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–1544
  40. Kampfer H, Pfeilschifter J, Frank S, et al. Expressional regulation of angiopoietin-1 and -2 and the tie-1 and -2 receptor tyrosine kinases during cutaneous wound healing: a comparative study of normal and impaired repair. Lab Invest. 2001;81:361–373
  41. Ahmad SA, Liu W, Jung YD, Fan F, Wilson M, Reinmuth N, et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res. 2001;61:1255–1259
  42. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 taht disrupts in vivo angiogenesis. Science. 1997;277(5322):55–60Jul 4
  43. Suri C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science. 1998;282(5388):468–471Oct 16
  44. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, et al. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest. 1999;79(2):213–223Feb
  45. Tait CR, Jones PF. Angiopoetins in tumors: The angiogenic switch. J Pathol. 2004;204:1–10
  46. Kumara S, Hoffman A, Nasar A, et al. Colorectal resection, open more so than minimally invasive in patients with benign indications is associated with proangiogenic changes in the plasma levels of angiopoietin 1 and 2. Surg Endoscopy. 2007;21:S352–S482
  47. Bishop ET, Bell GT, Bloor S, et al. An in vitro model of angiogenesis: basic features. Angiogenesis. 1999;3(4):335–344

PII: S1043-1489(07)00052-8

doi: 10.1053/j.scrs.2007.10.007

Seminars in Colon & Rectal Surgery
Volume 18, Issue 4 , Pages 242-246 , December 2007

Article Tools